Alvarez et al: Int J Neuropsychopharmacol, vol. 15, no. 5, 2012, page 589, (B1)

Worthington II et al: Drugs of Today, vol. 39, no. 11, 2003, page 887, (B1)

Anderson et al: J Psychopharmacol, vol. 22, no. 4, 2008, page 343, (B1)

Antai-Otong, D.: Perspect. Psychiatr. C., vol. 40, no. 1, 2004, page 29, (B1)

Anttila, S. et al: CNS Drug Reviews, vol. 7, no. 3, 2001, pages 249-264, (B1)

Ashton: Journal of sex & marital therapy, vol. 30, no. 1, 2004, page 1, (B1)

Assessment report for an initial marketing authorisation, European Medicines Agency, 24.10.2013 (as published 14.01.2014) (B1)

Baldwin et al: Europ. Neuropsychopharm, vol. 22, 2012, page 482, (B1)

Baldwin et al: J Clin. Psychiatry, vol. 67, no. sup 6, 2006, page 9, (B1)

Baron: Dtsch Arztebl, vol. 103, no. 41, 2006, page A 2720, (B1)

Buoen, C. et al: J. Clin. Pharmacol., vol. 45, 2005, pages 1123-1136, (B1)

Correll, C. U., Medscape (online article) (2013) (B1)

Curriculum Vitae for Dr Parmentier (B1)

Curriculum Vitae for Prof. Volz (B1)

De Battista et al: Biological psychiatry, vol. 44, no. 5, 1998, page 341, (B1)

Declaration of Dr Henk Parmentier (B1)

Declaration of Professor Hans-Peter Volz (B1)

Dharshaktu et al: J Clin. Pharmacol, vol. 52, no. 6, 2012, (B1)

FDA approved labelling for fluoxetine (Prozac) capsules and oral solution; action date 20.09.2006 (B1)

FDA approved labelling for sertraline (Zoloft )action date 14.09.2006 (B1)

Fava et al: Expert Rev Neurotherapeutics, vol. 6, no. 11, 2006, page 1735, (B1)

Fava et al: J. Clin. Psychiatry, vol. 63, no. sup 5, 2002, page 13, (B1)

Gregorian, R. et al: The Annals of Pharmacotherapy, vol. 36, 2002, pages 1577-1589, (B1)

Guidelines for Phase I Clinical Trials, The Association of the British Pharmaceutical Industry, London, 2007 Edition (B1)

Harvey, K. et al: Annals of Clinical Psychiatry, vol. 7, no. 4, 1995, pages 189-201, (B1)

Iyengar, S. et al: J. Pharmacol. Exp. Ther., vol. 311, no. 2, 2004, page 576, (B1)

Katona, C. et al: Int. Clin. Psychopharm., vol. 27, 2012, pages 215-223, (B1)

Khawam et al: Cleveland Clinic journal of medicine, vol. 73, no. 4, 2006, page 351, (B1)

LARSEN KARI: "Lundbeck says antidepressant LuAA21004 positive in phase II - shares jump" INTERNET ARTICLE, [Online] 2 October 2007 (2007-10-02), XP002509653 Retrieved from the Internet: URL:http://health.apmnews.com/depechesPubl ieesDepeches.php?annee=2007&mois=10&jour=2 > [retrieved on 2009-01-08] (B1)

MEALY N E ET AL: "Lu-31-130/Lu-AA-21004/Lu-35-138" DRUGS OF THE FUTURE 200409 ES, vol. 29, no. 9, September 2004 (2004-09), pages 954-955, XP009110475 ISSN: 0377-8282 (B1)

Margolese, H. et al: Journal of sex & marital therapy, vol. 22, no. 3, 1996, pages 209-217, (B1)

Moltzen and Bang-Andersen: Cuff Topic Med Chem, vol. 6, no. 17, 2006, page 1801, (B1)

NCDEU Annual Meeting; 31 May 2013, Hollywood, FL, USA (B1)

Preskorn, S. H. et al: Antidepressants: Past, Present and Future, vol. 157, 2004, pages 250-252, (B1)

Rothschild, A. J.: Clin. Ther., vol. 22, no. sup A, 2000, page A42, (B1)

Ruhe et al: The journal of clinical psychiatry, vol. 67, no. 12, 2006, page 1836, (B1)

Serretti, A. et al: J Clin Psychopharmacol., vol. 29, no. 3 , pages 259-266, (B1)

Spinks and Spinks: Cuff Med Chem, vol. 9, 2002, page 799, (B1)

Stahl: Int J Psychiatry in Clin. Prectice, vol. 8, no. 3, 2004, (B1)

Statement on a nonproprietary name adopted by the USAN council (B1)

Taylor et al: The Maudsley Prescribing Guidelines, Informa Healthcare, 9th Ed., 2007, pages 231-234, (B1)

To et al: BCMJ, vol. 44, no. 79, 2002, (B1)

Vissers, K. et al: Pharmacol. Biochem. Be., vol. 84, 2006, pages 479-486, (B1)

WO-A-03/029232 (B1)

WO-A-2007/144005 (B1)

WO-A-2008/113359 (B1)

WO-A1-03/029232 (B1)

WO-A1-2007/144005 (B1)

WO-A2-2008/113359 (B1)

Westenberg and Sandner: Int J Clin Pract., vol. 60, 2006, page 482, (B1)

Alvarez, E. et al: Int. J. Neuropsychoph., vol. 15, 2012, pages 589-600, (B1)